| Cumulative incidence of and predictive factors for lung cancer in IPF Y Ozawa, T Suda, T Naito, N Enomoto, D Hashimoto, T Fujisawa, ... Respirology 14 (5), 723-728, 2009 | 296 | 2009 |
| Efficacy and tolerability of high-flow nasal cannula oxygen therapy for hypoxemic respiratory failure in patients with interstitial lung disease with do-not-intubate orders: a … T Koyauchi, H Hasegawa, K Kanata, T Kakutani, Y Amano, Y Ozawa, ... Respiration 96 (4), 323-329, 2018 | 79 | 2018 |
| SKYSCRAPER-02: primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab+ carboplatin+ etoposide with or without tiragolumab in … CM Rudin, SV Liu, S Lu, RA Soo, MH Hong, JS Lee, M Bryl, D Dumoulin, ... Cancer (ES-SCLC) 1, 2, 2022 | 68 | 2022 |
| Possible therapeutic effect of direct haemoperfusion with a polymyxin B immobilized fibre column (PMX‐DHP) on pulmonary oxygenation in acute exacerbations of interstitial pneumonia N Enomoto, T Suda, T Uto, M Kato, Y Kaida, Y Ozawa, H Miyazaki, ... Respirology 13 (3), 452-460, 2008 | 67 | 2008 |
| Immune‐related adverse events by immune checkpoint inhibitors significantly predict durable efficacy even in responders with advanced non‐small cell lung cancer H Akamatsu, E Murakami, J Oyanagi, R Shibaki, T Kaki, E Takase, ... The Oncologist 25 (4), e679-e683, 2020 | 64 | 2020 |
| Impact of preexisting interstitial lung disease on acute, extensive radiation pneumonitis: retrospective analysis of patients with lung cancer Y Ozawa, T Abe, M Omae, T Matsui, M Kato, H Hasegawa, Y Enomoto, ... PloS one 10 (10), e0140437, 2015 | 64 | 2015 |
| Impact of early inflammatory cytokine elevation after commencement of PD-1 inhibitors to predict efficacy in patients with non-small cell lung cancer Y Ozawa, Y Amano, K Kanata, H Hasegwa, T Matsui, T Kakutani, ... Medical Oncology 36, 1-6, 2019 | 63 | 2019 |
| Management of brain metastasis with magnetic resonance imaging and stereotactic irradiation attenuated benefits of prophylactic cranial irradiation in patients with limited … Y Ozawa, M Omae, M Fujii, T Matsui, M Kato, S Sagisaka, K Asada, ... Bmc Cancer 15, 1-7, 2015 | 57 | 2015 |
| A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors … H Hayashi, S Sugawara, Y Fukuda, D Fujimoto, S Miura, K Ota, Y Ozawa, ... Clinical Cancer Research 28 (5), 893-902, 2022 | 51 | 2022 |
| YB1 binds to and represses the p16 tumor suppressor gene Y Kotake, Y Ozawa, M Harada, K Kitagawa, H Niida, Y Morita, K Tanaka, ... Genes to Cells 18 (11), 999-1006, 2013 | 30 | 2013 |
| Enhanced anti-tumor immunity by superantigen-pulsed dendritic cells M Kato, Y Nakamura, T Suda, Y Ozawa, N Inui, N Seo, T Nagata, Y Koide, ... Cancer Immunology, Immunotherapy 60, 1029-1038, 2011 | 30 | 2011 |
| Safety of topotecan monotherapy for relapsed small cell lung cancer patients with pre-existing interstitial lung disease Y Enomoto, N Inui, S Imokawa, M Karayama, H Hasegawa, Y Ozawa, ... Cancer chemotherapy and pharmacology 76, 499-505, 2015 | 24 | 2015 |
| Longitudinal evaluation of PD-L1 expression on circulating tumor cells in non-small cell lung cancer patients treated with nivolumab M Ikeda, Y Koh, S Teraoka, K Sato, J Oyanagi, A Hayata, N Tokudome, ... Cancers 13 (10), 2290, 2021 | 21 | 2021 |
| Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small cell lung cancer: a phase II clinical trial K Nakashima, Y Ozawa, H Daga, H Imai, M Tamiya, T Tokito, T Kawamura, ... Investigational new drugs 38, 1854-1861, 2020 | 21 | 2020 |
| Phase II study of combination chemotherapy with S-1 and weekly cisplatin in patients with previously untreated advanced non-small cell lung cancer Y Ozawa, N Inui, T Naitoh, K Yasuda, M Nagayama, T Shirai, ... Lung Cancer 63 (1), 68-71, 2009 | 21 | 2009 |
| Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small-cell lung cancer without epidermal growth factor receptor mutations S Matsuura, N Inui, Y Ozawa, Y Nakamura, M Toyoshima, K Yasuda, ... Japanese Journal of Clinical Oncology 41 (8), 959-963, 2011 | 19 | 2011 |
| Pembrolizumab plus amrubicin in patients with relapsed SCLC: multi-institutional, single-arm phase 2 study H Akamatsu, S Teraoka, H Hayashi, D Fujimoto, A Hayata, K Haratani, ... JTO Clinical and Research Reports 2 (7), 100184, 2021 | 16 | 2021 |
| Detection of AXL expression in circulating tumor cells of lung cancer patients using an automated microcavity array system M Ikeda, Y Koh, S Teraoka, K Sato, K Kanai, A Hayata, N Tokudome, ... Cancer medicine 9 (6), 2122-2133, 2020 | 15 | 2020 |
| Distinctive impact of pre-existing interstitial lung disease on the risk of chemotherapy-related lung injury in patients with lung cancer Y Ozawa, D Akahori, K Koda, T Abe, H Hasegawa, T Matsui, M Tanahashi, ... Cancer chemotherapy and pharmacology 77, 1031-1038, 2016 | 15 | 2016 |
| A case of bronchial infection of Wangiella dermatitidis Y Ozawa, T Suda, Y Kaida, M Kato, H Hasegaw, M Fujii, M Ida, ... Nihon Kokyuki Gakkai Zasshi= the Journal of the Japanese Respiratory Society …, 2007 | 14 | 2007 |
